Table 1.
Characteristic of the study subjects
| CGN with NS (n = 42) | CGN without NS (n = 34) | Positive controls (n = 10) | Negative controls (n = 10) | |
|---|---|---|---|---|
| Age, years | 40.4 [24–53] | 36.4 [26–49] | 34 [23–45] | 31 [28–37] |
| Gender (males), n (%) | 24 (57) | 19 (56) | 5 (50) | 5 (50) |
| Kidney histology, n (%) | 40 (95.2) | 22 (64.7) | – | – |
| MCD | 5 (12.5) | 0 | – | – |
| FSGS | 5 (12.5) | 2 (9.1) | – | – |
| MN | 10 (25) | 3 (13.6) | – | – |
| MPGN | 6 (15) | 5 (22.7) | – | – |
| IgA nephropathy | 18 (45) | 12 (54.5) | – | – |
| Arterial hypertension, n (%) | 37 | 30 | 2 | 0 |
| Proteinuria, g/24 h | 6.12 [4.37–10.0] | 1.9 [1.4–3.2] | 0.48 [0.16–0.78] | 0 |
| Serum albumin, g/L | 25.6 [21.3–30.7] | 39.8 [37.5–42.4] | 43.8 [41.2–46.1] | – |
| Creatinine, μmol/L | 1.1 [0.85–1.65] | 1.06 [0.8–1.5] | 1.03 [0.84–1.5] | – |
| eGFR, ml/min/1.73 m2 | 87.29 [50–116] | 81.0 [54–112] | 98 [68–125] | – |
| eGFR < 60 ml/min/1.73 m2, n (%) | 14 (33.3) | 7 (20.6) | 2 (20) | – |
| Immunosupressive therapy, n (%) | 23 (54.8) | 15 (44.1) | 0 | 0 |
| Oral corticosteroids | 6 (26) | 4 (26.7) | 0 | 0 |
| Pulse MP/CYC | 12 (52.2) | 7 (46.6) | 0 | 0 |
| Cyclosporine A | 5 (21.7) | 4 (26.7) | 0 | 0 |
MP methylprednisolone, CYC cyclophosphamide, MCD minimal change disease, FSGS focal segmental glomerular sclerosis, MN membranous nephropathy, MPGN membranoproliferative glomerulonephritis, eGFR estimated glomerular filtration rate